

A Concise Approach to the Polycyclic Scaffold of Frondosin D

Kye-Simeon Masters and Bernard L. Flynn*

Department of Medicinal Chemistry, Victorian College of Pharmacy, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia

bernard.flynn@vcp.monash.edu.au

Received April 2, 2008



In a study directed at developing a concise approach to the polycyclic core of frondosin D, a Stille–Heck sequence has been identified that gives direct access to the trimethylbicyclo [5.4.0]undecane ring system common to all frondosins.

Frondosins A–E, **1–5** (Figure 1), are a family of related marine sesquiterpenoids first isolated in their *dextro*-rotatory form from the sponge *Dysidea frondosa*.^{1a} Additionally, *levo*-rotatory frondosins A and D were isolated from an unidentified *Eurospongia* species.^{1b} Frondosins A–E are compounds of interest due to their promising interleukin-8 (IL-8) affinity and protein kinase C inhibition.^{1a} IL-8 antagonists are of particular interest in view of their antiinflammatory,^{2a} anti-HIV, ^{1b,2b} and antitumor^{2c–f} properties. To date, frondosins A, B, and C have been synthesized.³ Notwithstanding these successes, the fron-

10.1021/jo800682n CCC: \$40.75 © 2008 American Chemical Society Published on Web 09/18/2008

dosins have proved quite a formidable synthetic challenge, and as of yet, there has been no synthesis of frondosin D or E. In this report, we describe our approaches to the molecular scaffold of frondosins D. This work has culminated in a very effective means of producing the trimethylbicyclo[5.4.0]undecane ring system common to all frondosins (shown in bold, Figure 1).



FIGURE 1. (+)-Frondosins A-E.⁴

Our retrosynthetic analysis of frondosin D focuses on accessing prochiral tetracycle **6** (Scheme 1), which could feasibly deliver frondosin D through a sequence of asymmetric double bond reduction,⁵ phenylmethyl ether cleavage and oxidation.^{3h} In this report, we will describe our assessment of different approaches to this key tetracycle **6**.

In our initial approach to **6**, we anticipated performing ring closing metathesis (RCM) on **7** similar to that used in our frondosin B synthesis (Scheme 1).^{3e} We envisaged that chromene **7** could be accessed through Kumada–Corriu coupling of isopropenylmagnesium bromide with iodide **8**, which in turn could be formed by 1,6-*endodigonal* iodocyclization of **9**, which results from the 1,2-addition of lithium acetylide **11** to known ketone **10**,⁶ followed by regioselective elimination of H₂O.⁷

A key step in our initially proposed access to frondosin D (4) is the 1.6-endodigonal iodocyclization of 9 to give 8. At the time of conducting this work, such iodocyclizations to form 3-iodochromenes had not been reported and we undertook a brief model study to verify this key step (Scheme 2).⁸ This work revealed that the sequence of 1,2-addition to give 12 (92%), followed by elimination of H_2O to give 13 (82%), albeit with a small amount of chloroallene 14 (11%) byproduct, could be readily acheived.⁹ Iodocyclization of 13 was best achieved using I2 in CH3CN or THF with K2CO3 as base, affording the 1,6endodigonal cyclization product, 2-iodochromene 14 in good yield (83%). However, we noted that success in this reaction was dependent on the use of anhydrous solvent, and that a specific byproduct was formed in wet solvents. This byproduct was determined to be the 1,5-endodigonal cyclization product 16. This byproduct was formed as the exclusive product of the reaction when a solvent combination of THF/H₂O (99:1) was

- (5) Roseblade, S. J.; Pfaltz, A. Acc. Chem. Res. 2007, 40, 1402-1411.
- (6) (a) Näf, F.; Decorzant, R. *Helv. Chim. Acta* **1974**, *57*, 1317. (b) Magatti,
- C. V.; Kaminski, J. J.; Rothberg, I. J. Org. Chem. 1991, 56, 3102.
 (7) Knölker, H.-J.; Ecker, A.; Neef, G. Tetrahedron 1996, 53, 91–108.
- (8) (a) Barluenga, J.; Trincado, M.; Marcos.Arias, M.; Ballestros, A.; Rubio, E.; Gonzalez, J. M. Chem. Commun. 2005, 2008–2010.

^{(1) (}a) Patil, A. D.; Freyer, A. J.; Killmer, L.; Offen, P.; Carte, B.; Jurewicz, A. J.; Johnson, R. K. *Tetrahedron* **1997**, *53*, 5047–5060. (b) Hallock, Y. F.; Cardellina, J. H., II; Boyd, M. R. *Nat. Prod. Lett* **1998**, *11*, 153–160.

^{(2) (}a) Seitz, M.; DeŴald, B.; Gerber, N.; Baggioni, M. J. Clin. Invest. 1991, 87, 463–469. (b) Lane, B. R.; Paul, K. L.; Block, J.; Andersson, J.; Coffey, M. J.; Strieter, R. M.; Markovitz, D. M. J. Virol. 2001, 57, 8195–8202. (c) Karashima, T.; Sweeney, P.; Kamat, A.; Huang, S.; Kim, S. J.; McConkey, D. J.; Dinney, C. P. Clin. Cancer Res. 2003, 9, 2786–2797. (d) Zhu, Y. M.; Webster, S. J.; Flower, D.; Woll, P. J. Br. J. Cancer. 2004, 91, 1970–1976. (e) Mian, B. M.; Dinney, C. P.; Bermejo, C. E.; Sweeney, P.; Tellez, C.; Yang, X. D.; Gudas, J. M.; McConkey, D. J.; Bar-Eli, M. Clin. Cancer Res. 2003, 9, 3167–3175. (f) Brat, D. J.; Bellail, A. C.; Van-Meir, E. G. Neuro-oncol. 2005, 7, 122–133.

^{(3) (}a) Inoue, M.; Frontier, A. J.; Danishefsky, S. J. Angew. Chem., Int. Ed. 2000, 39, 761–764. (b) Inoue, M.; Carson, M. W.; Frontier, A. J.; Danishefsky, S. J. J. Am. Chem. Soc. 2001, 123, 1878–1889. (c) Hughes, C. C.; Trauner, D. Angew. Chem., Int. Ed. 2002, 41, 1569–1572. (d) Hughes, C. C.; Trauner, D. Tetrahedron 2004, 60, 9675–9686. (e) Kerr, D. J.; Willis, A. C.; Flynn, B. L. Org. Lett. 2004, 6, 457. (f) Martinez, I.; Alford, P. E.; Ovaska, T. V. Org. Lett. 2005, 7, 1133–1135. (g) Li, X.; Kyne, R. E.; Ovaska, T. V. Org. Lett. 2006, 8, 5153. (h) Li, X.; Kyne, R. E.; Ovaska, T. V. Org. Lett. 2006, 8, 11790. (j) Li, X.; Ovaska, T. V. Org. Lett. 2007, 9, 3837–3840.

⁽⁴⁾ The absolute stereochemistry depicted for (+)-frondosins is tentatively depicted as β -methyl based on previous asymmetric synthesis efforts; see ref 3i and references cited therein.

⁽⁹⁾ Presumably, 14 is formed by S_N2' substitution of the intermediate sulfenate ester by a chloride ion. (a) Bhatia, Y. R.; Landor, P. D.; Landor, S. R. J. Am. Chem. Soc. 1959, 81, 24–29. (b) Mori, K.; Watanabe, H. Tetrahedron 1986, 42, 273–281. (c) Soukup, M.; Widmer, E.; Lukáč, T. Helv. Chim. Acta 1990, 73, 868–873.





SCHEME 2. Model Iodocyclization and Coupling Study



employed (70% isolated yield). At no time in this study did we detect any 1,5-*exocyclization* product **17**.

While the previous studies on 1,6-endodigonal iodocyclization to 2-iodochromenes did not report the formation of the 1,5endodigonal product, some related cyclizations have been recently reported.¹⁰ On the basis of these previous reports, connection of the alkyne through an electron-releasing ether group would be expected to direct nucleophilic attack of the activated alkyne through the *ortho* position of the phenyl ring in intermediate 19 to give 20 then 15 (Scheme 3). However, this ortho-directing effect of this ether tether appears to be overridden by the para-directing effect of the methoxy group, effectively giving an ipso-attack of the phenyl group upon the tethered alkyne, giving intermediate 21 in a 1,5-endodigonal cyclization. In the presence of water, 21 is "trapped", giving the spirocyclic product 16.^{10a} In the absence of water, the initially formed intermediate 21 funnels back through 19 to give the intermediate 20, which undergoes irreversible proton elimination to give 15. Alternatively, kinetically formed 21 migrates directly to 20 prior to trapping.



SCHEME 4. Preparation of Cyclohexanone 10



SCHEME 5. Attempted Iodocyclization Pathway to 7



Kumada–Corriu coupling of **15** with isopropenylmagnesium bromide was successfully employed in giving **18** (69%) (Scheme 2).

On the basis of this successful access of **18**, we prepared cyclohexanone **10**, which bears the requisite substitution pattern for application to the synthesis of tetracycle **7** (Scheme 4). Compound **10** was accessed from dione **22** by initial conversion to **23**,¹¹ followed by a one-pot addition–elimination–addition sequence with methylcuprate, giving **10** in good yield (77%).

Unfortunately, application of **10** to the preparation of **7** was not successful (Scheme 5). Initial lithiation and 1,2-addition of alkyne **11** to cyclohexanone **10** proceeded well to give alcohol **24** as a single diastereomer (78%), but the elimination reaction gave an inseparable mixture of products **9**, **25**, and **26** (both diastereomers) in a 5:3:2 ratio by ¹H NMR.¹² Nonetheless,

^{(10) (}a) Appel, T. R.; Yehia, N. A. M.; Baumeister, U.; Hartung, H; Kluge, R.; Ströhl, D.; Fanghänel, E. *Eur. J. Org. Chem.* **2003**, 47–53. (b) Barluenga, J.; Palomas, D.; Rubio, E.; Gonzalez, J. M. *Org. Lett.* **2007**, *9*, 2823–2826. (c) Zhang, X.; Larock, R. C. *J. Am. Chem. Soc.* **2005**, *127*, 12230–12231. (d) Ren, X.-F.; Turos, E.; Lake, C. H.; Churchill, M. R. J. *Org. Chem.* **1995**, *60*, 6468.

⁽¹¹⁾ Piers, E.; Grierson, J. R.; Lau, C. K.; Nagakura, I. Can. J. Chem. 1982, 60, 210–223.

⁽¹²⁾ Investigation of alternative conditions included a reduction of temperature to -78 °C, which gave similar results, and the use of alternatives to SO₂Cl₂ such as POCl₃, TsCl, or Tf₂O led to worse outcomes.

SCHEME 6. Revised Approach to Frondosin D Core 6



SCHEME 7. Preparation of α,β -Diactivated Chromenes



treatment of the mixture with iodine gave 3-iodochromene 8 in 44% yield from 24. Attempted Kumada–Corriu coupling of 8 with isopropenylmagnesium bromide did not yield the intended coupling product 7 but gave exclusive formation of 27, which had resulted from an intermolecular 1,6-*exotrigonal* Heck cyclization of 8.

We revised our plan to take advantage of this facile Heck reaction and to avoid the requirement to prepare 9. In the revised plan, an α,β -diactivated chromene 28 is employed in a reaction sequence involving a Stille then Heck reaction (Stille–Heck reaction) with 29 to give 30, which is then *gem*-dimethylated to give 6 (Scheme 6).^{13,14}

A considerable component of this work focused on selecting the correct arrangement of activating groups in **28**. The positioning of the functional groups, halide and triflate, in **28a**–**d** was based on the relative reactivity of these different groups with palladium(0) (usually I > OTf > Br \gg Cl), such that a domino or stepwise Stille–Heck sequence with **29** will proceed with the correct regioselectivity to give **30**.

We prepared **28a** and **28b** by halocyclization of the iodoalkyne **31** using *N*-bromosuccinimde (NBS) and *N*-chlorosuccinimde (NCS), respectively (Scheme 7).⁸ 1-Trifloxy-2bromo/chlorochromenes **28c** and **28d** were both prepared from chromanone **32** by initial α -halogenation with CuBr₂ or SO₂Cl₂ giving **33** and **34**, respectively, followed by enoltriflation (Scheme 7).^{15,16}

Stannylcyclohexenone **29** was prepared by a variation of the method previously developed by Piers et al. (Scheme 8).¹⁷ 1,3-







Cyclohexanedione **35** was converted to bromoenone **36** (93%) and the bromo group substituted for a stannyl group using $(Me_3Sn)_2Cu$ ·LiCN, giving **29** (90%).

We next turned to evaluating the proposed Stille–Heck sequence on the various α,β -diactivated chromene systems **28a**–**d** (Scheme 9). Our optimal method for performing Stille couplings involved Pd(dba)₂, tri-(2-furyl)phosphine (TFP), ZnCl₂, and copper(I) thiophenecarboxylate (CuTPC) in *N*-methylpyrrolidine (NMP) (Method A).^{18,19} Also, for reactions where we anticipated that a subsequent Heck reaction may occur in situ, such as domino reaction of iodobromide **28a** or bromotriflate **28c**, we added the hindered base Cy₂NMe to ensure continual recycling of the catalyst (Method B).

In the case of the 1-iodo-2-bromochromene **28a**, the use of Method A or B led to rapid formation of a very complex reaction mixture with no discernible product formation. When the corresponding 1-iodo-2-chlorochromene **28b** was reacted with **29** using Method A, only a low yield of the coupled product **38** (<5%) was acheived. Attempted coupling of **28b** under slightly modified conditions using Pd(PPh₃)₄, LiCl, and CuTPC in NMP (Method C) returned a superior yet unsatisfying yield of **38** (36%). We did not further attempt to optimize coupling of either of iodochromenes **28a** or **28b** with **29** but focused instead on the more stable bromo- and chlorotriflates **28c** and **28d**. Using

⁽¹³⁾ The use of doubly activated alkenes in sequential Stille-Heck processes has been previously reported by de Meijere and co-workers: (a) Sünnemann, H.-W.; de Meijere, A. Angew. Chem., Int. Ed. 2004, 13, 895-897. (b) Voigt, K.; von Zezschwitz, P.; Rosauer, K.; Lansky, A.; Adams, A.; Reiser, O.; de Meijere, A. Eur. J. Org. Chem. 1998, 1521–1534. (c) von Zezschwitz, P.; Petry, F.; de Meijere, A. Chem.-Eur. J. 2001, 7, 4035-4046.

⁽¹⁴⁾ For related gem-dimethylations, see refs 3e and 3d.

⁽¹⁵⁾ Dewald, H. A.; Heffner, T. G.; Jaen, J. C.; Lustgarten, D. M.; McPhail,

A. T.; Meltzer, L. T.; Pugsley, T. A.; Wise, L. D. J. Med. Chem. 1990, 33, 445-450.

 ^{(16) (}a) Comins, D. L.; Dehghani, A. Tetrahedron Lett. 1992, 33, 6299–6302.
 (b) Pal, K. Synthesis 1995, 1485–1487.

 ^{(17) (}a) Piers, E.; Morton, H. E. J. Chem. Soc., Chem. Commun. 1978, 1033–1034.
 (b) Piers, E.; Morton, H. E.; Chong, J. M. Can. J. Chem. 1987, 65, 78–87.

^{(18) (}a) Farina, V.; Baker, S. R.; Sapino, C, Jr *Tetrahedron Lett.* 1988, 29, 6043–6046. (b) Farina, V.; Roth, G. P. *Tetrahedron Lett.* 1991, 32, 4243–4246.
(c) Kapadia, S.; Krishnan, B.; Wang, C.; Liebeskind, L. S. J. Org. Chem. 1994, 59, 5905–5911.

⁽¹⁹⁾ Allred, G. D.; Liebeskind, L. S. J. Am. Chem. Soc. 1996, 118, 2748-2749.

JOC Note

Method A, **28c** coupled to **29** in a domino Stille–Heck sequence to give **30** as a mixture of double bond isomers (**30a/b**) in a respectable yield (50%). Unfortunately, this material was contaminated by significant amounts of the bromo-reduced material **37** (23%), and it was not possible to separate these two products.

Using Method A with 2-chloroalkenyl triflate **28d**, we were able to achieve an excellent yield of the Stille product **38** (88%). Although alkenyl chlorides are not very reactive substrates for Heck reactions, by using $Pd^{0}(t-Bu_{3}P)_{2}$ as a catalyst, the 1,7-intramolecular Heck cyclization of **38** to **30a/b** (mixture of double bond isomers) was acheived in excellent yield (84%). This mixture was quantitatively converted to the thermodynamically most stable *endo*-isomer **30b** upon heating in anhydrous EtOH with catalytic RhCl₃.

Ketone **30b** was converted to *gem*-dimethylated tetracycle **6** using a variation of the Reetz conditions developed by Trauner and co-workers.^{3c,d} This involves initial reaction of the ketone with MeMgBr to give a tertiary alcohol (not shown), followed by reaction with Me₂TiCl₂ to give **6** (77%), the structural framework of frondosins D and E (**4** and **5**, respectively).

Experimental Section

2-(But-3-enyl)-3-(3-chloro-6-methoxy-2H-chromen-4-yl)cyclohex-2-enone (38). ZnCl₂ (708 mg, 5.00 mmol) was flame dried carefully in a round-bottomed flask under vacuum and backfilled with N2(g), then NMP (18 mL) was added, the reaction vessel was evacuated and backfilled with N2(g), and 2-chloroalkenyl triflate 28d (500 mg, 1.45 mmol), Pd(dba)₂ (83 mg, 0.145 mmol), TFP (68 mg, 0.29 mmol), CuTPC (28 mg, 0.147 mmol), and stannane 29 (654 mg, 2.03 mmol) were all added. The reaction mixture was heated to 55 $^{\circ}$ C in an oil bath under N₂(g). After 2.5 h, the starting materials were consumed (TLC analysis), the reaction was cooled to rt and poured onto a plug of alumina (neutral, Brockmann grade I), and the organics were washed through with Et₂O (100 mL). The organics were washed with H_2O (4 \times 100 mL) and dried over MgSO₄, and the volatiles were removed under reduced pressure. Column chromatography of the brown crude on silica gel with EtOAc-PS (1:19 then 7:93) delivered chloride 38 (438 mg, 1.27 mmol, 88%) as a colorless viscous gum: ¹H NMR (300 MHz, $CDCl_3$) δ 6.88 (d, J = 8.7 Hz, 1H), 6.77 (dd, J = 8.7, 3.0 Hz, 1H), $6.45 (d, J = 3.0 Hz, 1H), 5.82 - 5.65 (m_c, 1H), 4.98 - 4.88 (m, 2H),$ 4.86 (d, J = 5.4 Hz, 2H), 3.78 (s, 3H), 2.65–2.55 (m, 1H), 2.59 (t, J = 6.9 Hz, 2H), 2.47–2.30 (m, 2H), 2.26–2.17 (m, 3H), 2.16–2.12 (t, J = 6.9 Hz, 2H); ¹³C NMR (75.5 MHz, CDCl₃) δ 183.8 (C=O), 154.7 (C), 150.2 (C), 146.5 (C), 139.0 (C), 138.5 (CH), 132.0 (C), 121.6 (C), 121.4 (C), 116.8 (CH), 114.5 (CH₂), 114.0 (CH), 110.5 (CH), 68.7 (CH₂), 55.8 (CH₃), 38.3 (CH₂), 32.7 (CH₂), 29.9 (CH₂), 27.0 (CH₂), 22.7 (CH₂); IR (cm⁻¹) 1672; HRMS (ESI) calcd for $[C_{20}H_{22}ClO_3]^+$ (M + H⁺) 345.1252, found 345.1244.

2-Methoxy-7-methyl-9,11,12,13-tetrahydro-6H-5-oxabenzo[6,7] cyclohepta[1,2-a]naphthalene-10-one (30b). Method A: (from alkenylchloride 38) Cs₂CO₃ (1.25 g, 3.83 mmol) was flame dried in a Schlenk tube under vacuum and backfilled with $N_2(g)$. NMP (7) mL) was added, and the stirring suspension was degassed [evacuated and backfilled with $N_2(g)$]. Pd(t-Bu₃P)₂ (355 mg, 0.70 mmol) was added and the suspension stirred at 85 °C for 0.2 h (catalyst dissolves), then alkenylchloride **38** (1.20 g, 3.48 mmol) was added, and the reaction was stirred for 2 h, after which time the starting material 38 was consumed by TLC. The reaction mixture was passed through a plug of alumina (neutral, Brockmann grade I) rinsing with Et₂O. The Et₂O filtrate was washed with H₂O (4 \times 100 mL) and brine (50 mL) and dried with MgSO4, and the volatiles were removed under reduced pressure to give a brown crude product. Column chromatography of the crude on silica gel with Et₂O-PS (9:41 then 11:39) delivered tetracycles 30a/b (901 mg, 2.92 mmol, 84%) as a pale yellow gum.

RhCl₃ (3.7 mg, 5 mol %) was added to a stirred solution of tetracycles 30a/b (57.0 mg, 0.185 mmol) in EtOH (4 mL) under N₂(g). The mixture was heated to 75 °C and stirred for 7 h, then cooled, poured into H₂O (30 mL), and extracted with Et₂O (3 \times 10 mL). The combined extracts were dried over MgSO₄ and concentrated under reduced pressure to deliver tetracycle 30b (57.0 mg, 0.185 mmol, 100%) as a thick colorless gum which solidified upon standing at -20 °C. This compound was recrystallized from Et₂O-PS to pale-yellow square crystals: mp 119.5-121.5 °C; ¹H NMR (300 MHz, CDCl₃) δ 6.93 (d, J = 8.7 Hz, 1H), 6.92 (dd, J= 8.7, 2.7 Hz, 1H), 6.59 (d, J = 2.7 Hz, 1H), 5.75 (dt, J = 7.2, 1.2Hz, 1H), 5.07 (d, J = 14.4 Hz, 1H), 4.53 (d, J = 14.4 Hz, 1H), 3.78 (s, 3H), 3.60 (dd, J = 12.6, 8.1 Hz, 1H), 2.89 (m, 1H), 2.70-2.30 (m, 3H), 2.2-1.85 (m, 2H), 2.00 (s, 3H), 1.65 (dd, J =12.6, 8.1 Hz, 1H); ¹³C NMR (75.5 MHz, CDCl₃) δ 197.6 (C=O), 154.5 (C), 148.4 (C), 146.9 (C), 138.5 (C), 134.6 (C), 134.1 (C), 131.0 (C), 130.1 (CH), 124.5 (C), 117.1 (CH), 114.3 (CH), 113.2 (CH), 66.8 (CH₂), 55.8 (CH₃), 38.4 (CH₂), 29.7 (CH₂), 24.1 (CH₂), 23.7 (CH₂), 20.8 (CH₃); IR (cm⁻¹) 1671; LRMS (+ESI) calcd 308.9; HRMS (+ESI) calcd $[C_{20}H_{21}O_3]^+$ (M + H⁺) 309.1485, found 309.1486.

Supporting Information Available: Experimental details and copies of ¹H NMR and ¹³C NMR spectra for all other compounds can be found in the Supporting Information. This material is available free of charge via the Internet at http://pubs.acs.org.

JO800682N